Publication: Evaluación de la implantación de un sistema de trazabilidad mediante lectura de código de barras en el proceso farmacoterapéutico del paciente oncológico
Loading...
Files
Official URL
Full text at PDC
Publication Date
2018-03-01
Authors
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidad Complutense de Madrid
Citations
Exportar
Abstract
Los Errores de Medicación (EM), entendidos como cualquier incidente prevenible que puede causar daño al paciente o dar lugar a un uso inapropiado de los medicamentos, pueden afectar a los fármacos utilizados en el PFTO pudiendo llegar a causar, desde daños irreversibles hasta la muerte del paciente. Diversas organizaciones internacionales como nacionales han mostrado su preocupación por los errores cometidos en los hospitales. En este sentido, diversos autores han puesto de manifiesto la importancia de la prevención de los EM con los fármacos utilizados en el tratamiento de los pacientes oncológicos. Por ello, el conocimiento de los procesos de la cadena terapéutica relacionada con el paciente oncológico, donde se producen con mayor frecuencia los EM es útil para establecer estrategias de prevención e incrementar la seguridad de la administración de estos fármacos a los pacientes. Las tecnologías aplicadas al PFT en general, y al oncológico en particular, han permitido la detección y prevención de EM, aumentando la seguridad de los pacientes. La aplicación de procesos tecnológicos, han sido recomendados por los principales organismos preocupados por la seguridad en la utilización de medicamentos, recomendando el uso de los mismos para detectar y prevenir los EM. Entre las aportaciones tecnológicas recomendadas, se encuentran la Prescripción Electrónica Asistida (PEA), la utilización de sistemas robotizados, utilización de Códigos de Barras (CB) y sistemas de Radiofrecuencia (RFID)...
Medication Errors (ME), understood as any preventable incident that can cause harm to the patient or result in improper use of medications, can affect the drugs used in the PFTO and can cause, irreversible damage or the death of a patient. Several international and national organizations have expressed concern about hospital errors. In this sense, several authors have demonstrated the importance of MŚs prevention with drugs used in the treatment of cancer patients. Therefore, knowledge of the therapeutic chain processes related to cancer patients, where MS occur more often, is useful to establish prevention strategies and increase the safety of the administration of these drugs to patients. The technologies applied to PFT in general, and oncological tests in particular, have enabled the detection and prevention of MS, increasing patient́s safety. The application of technological processes, have been recommended by the main agencies concerned with the safety in the use of medicines, recommending the use of those to detect and prevent MS. Among the recommended technological inputs are Electronic Prescription (EAP), the use of robotic systems, the use of Bar Codes (CB) and Radio Frequency Systems (RFID). The use of CB allows the unambiguous identification of both the drug and the patient. This system consisting of a coding by bars and spaces can include information, which uniquely identifies the patient and the drug, allowing the druǵs traceability throughout the PFT from its inception to the end of it...
Medication Errors (ME), understood as any preventable incident that can cause harm to the patient or result in improper use of medications, can affect the drugs used in the PFTO and can cause, irreversible damage or the death of a patient. Several international and national organizations have expressed concern about hospital errors. In this sense, several authors have demonstrated the importance of MŚs prevention with drugs used in the treatment of cancer patients. Therefore, knowledge of the therapeutic chain processes related to cancer patients, where MS occur more often, is useful to establish prevention strategies and increase the safety of the administration of these drugs to patients. The technologies applied to PFT in general, and oncological tests in particular, have enabled the detection and prevention of MS, increasing patient́s safety. The application of technological processes, have been recommended by the main agencies concerned with the safety in the use of medicines, recommending the use of those to detect and prevent MS. Among the recommended technological inputs are Electronic Prescription (EAP), the use of robotic systems, the use of Bar Codes (CB) and Radio Frequency Systems (RFID). The use of CB allows the unambiguous identification of both the drug and the patient. This system consisting of a coding by bars and spaces can include information, which uniquely identifies the patient and the drug, allowing the druǵs traceability throughout the PFT from its inception to the end of it...
Description
Tesis inédita de la Universidad Complutense de Madrid, Facultad de Farmacia, Departamento de Farmacología, leída el 03-07-2017